AZN - AstraZeneca PLC
| Previous Close | 36.44 |
| Open | 35.43 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 35.42 - 36.67 |
| 52 Week Range | 28.43 - 36.75 |
| Volume | 5,758,461 |
| Avg. Volume | 3,897,816 |
| Market Cap | 90.466B |
| Beta | 0.57 |
| PE Ratio (TTM) | 30.66 |
| EPS (TTM) | 1.18 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.97%) |
| Ex-Dividend Date | 2018-02-15 |
| 1y Target Est | 38.89 |
- Business Wire•2 days ago
LOKELMATM Approved in the US for the Treatment of Adults with Hyperkalemia
AstraZeneca today announced that the US Food and Drug Administration has approved LOKELMATM , formerly ZS-9, for the treatment of
- Investor's Business Daily•2 days ago
AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?
AstraZeneca dipped early Friday after the U.K.-based pharmaceutical company lagged first-quarter expectations for sales and core earnings.
Yahoo Finance•2 days agoTrump talks to Postmaster General about Amazon, plus a retail wrap-up and royal wedding preview
If you’re looking for a winner this week, the energy sector is the top performer, up 2.7%. Let’s take a look at some of today’s winners and losers. Stocks in the red include Campbell Soup, as the stock plummets with news that the CEO is retiring.
- Zacks•2 days ago
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Motley Fool•2 days agoAstrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript
AZN earnings call for the period ending March 31, 2018.
Reuters•2 days agoAstraZeneca pay report rejected by 35 percent of shareholders
More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.
Reuters•2 days agoAstraZeneca pay report rejected by 35 percent of shareholders
More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.
- MarketWatch•3 days ago
U.K. stocks fall from record as AstraZeneca, mining stocks decline
FTSE 100 on track for longest weekly win run since 2005ReutersAstraZeneca shares are losing ground Friday. U.K. stocks ended lower on Friday, pulling back from the previous session’s record close, as shares of AstraZeneca declined following the heavyweight drugmaker’s earnings report, and as shares in mining companies skidded in the wake of a selloff in metals prices. The FTSE 100 index (^FTSE) dropped 0.1% to close at 7,778.79, breaking a three-day winning streak.
- InvestorPlace•3 days ago
AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales
AstraZeneca plc’s earnings report for the first quarter of the year includes earnings per share of 27 cents. This is down from its earnings per share of 48 cents reported in the same period of the year prior. During the first quarter of 2018, AstraZeneca plc reported profit of $316 million.
- Zacks•3 days ago
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
- Market Realist•3 days ago
European Markets Are Mixed Early on May 18
The United Kingdom’s FTSE 100 Index started this week on a mixed note but regained strength as the week progressed. On Thursday, the FTSE 100 Index surged and closed higher at a fresh record high price levels. On May 18, the FTSE 100 Index opened slightly lower and consolidated near all-time high price levels in the morning session.
- Benzinga•3 days ago
Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...
- MarketWatch•3 days ago
Italian stocks lead Europe lower as politics spook traders
The Stoxx Europe 600 index (^STOXX) tipped about 0.1% lower to 395.44, on track to break a three-day winning run. Italy’s FTSE MIB Index (MTAA:FTSEMIB.MI) slumped 1% to 23,564.03, as political developments in the country flustered markets. In the U.K., the FTSE 100 index (^FTSE) slipped 0.2% to 7,774.39, but was still on track for a 0.6% weekly advance.
Reuters•3 days agoAstraZeneca insists future is bright after big Crestor sales hit
AstraZeneca's (AZN.L) first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million (663 million pounds), well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.
- Reuters•3 days ago
AstraZeneca insists future is bright after big Crestor sales hit
AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million, well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.
- Associated Press•3 days ago
Astrazeneca: 1Q Earnings Snapshot
On a per-share basis, the Cambridge, Britain-based company said it had net income of 27 cents. Earnings, adjusted for non-recurring costs, came to 48 cents per share. The results topped Wall Street expectations. ...
- The Wall Street Journal•3 days ago
[$$] AstraZeneca Profit Slides
PLC (AZN.LN) said Friday that first-quarter profit fell 37% despite a slight rise in sales, citing divestment timing as one of the factors that hurt its overall results. The drug maker said net profit was $340 million, compared with $537 million in the first quarter of 2017 and a consensus forecast of $114.2 million, according to five analysts polled by FactSet.
- Financial Times•3 days ago
[$$] AstraZeneca: appliance of science
when fending off Pfizer’s advances in 2014 are looking soft. With its scientific research starting to power rapid growth, investors can afford to give the Anglo-Swedish drugs company the benefit of the doubt. Sales dropped after a faster-than-expected decline in AstraZeneca’s cholesterol-zapping drug Crestor.
- Financial Times•3 days ago
[$$] AstraZeneca chief Pascal Soriot suffers pay revolt
suffered a significant revolt over the pay of its chief executive Pascal Soriot on Friday, when about 35 per cent of shareholders at its annual meeting voted against its remuneration report. Mr Soriot earned £9.4m in 2017, down from £14.3m a year earlier, but ISS had complained about the level of annual bonuses he had received, suggesting that the remuneration committee should have set more stringent targets. Pointing to the sales the company is garnering from its new medicines, one insider said that Mr Soriot was being “rewarded for turning science into products”.
- Financial Times•3 days ago
[$$] Stocks to watch: Vodafone, AstraZeneca, Glencore, Campbell Soup
fell by their most in almost two years on Friday, down as much as 8.7 per cent after a report said the miner may face a bribery probe by the UK’s Serious Fraud Office over its ties to Israeli billionaire Dan Gertler in the Democratic Republic of Congo. The SFO is planning to seek formal approval for a probe into Glencore’s dealings in the country with its former business partner Mr Gertler, Bloomberg News reported.
Market Realist•3 days agoImmunomedics Announces Positive Phase 2 Results
Today, Immunomedics (IMMU) announced positive results from a Phase 2 trial evaluating its investigational antibody drug conjugate (or ADC) sacituzumab govitecan in patients suffering from estrogen receptor-positive (or ER+)/human epidermal growth factor receptor 2-negative (or HER2-) metastatic breast cancer who have previously received at least two therapies. The investigational ADC therapy demonstrated an overall response rate of 31% in these heavily pretreated patients. Immunomedics plans to file its first biologics license application with the FDA later this month for the approval of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer (mTNBC).
- Zacks•4 days ago
Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?
AstraZeneca (AZN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
- Market Realist•5 days ago
Analysts’ Recommendations for AstraZeneca as of May 15
Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017. AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date.
- Market Realist•5 days ago
AstraZeneca’s 1Q18 Estimates: CVMD Products
AstraZeneca’s (AZN) Cardiovascular and Metabolic Disease (or CVMD) segment includes various products such as Brilinta, Farxiga, Bydureon, Byetta, Onglyza, and Symlin and legacy products such as Atacand, Crestor, and Seloken.
- Motley Fool•5 days ago
3 Dividend Stocks to Fund Your Nest Egg
A big yield worth risking and two small yields worth owning.
